Risk factors for Pseudomonas aeruginosa colonization in non-cystic fibrosis bronchiectasis and clinical implications

Respir Res. 2021 Apr 28;22(1):132. doi: 10.1186/s12931-021-01729-5.

Abstract

Background: Pseudomonas aeruginosa is one of the commonest bacteria colonizing the airway in patients with non-cystic fibrosis bronchiectasis. Pseudomonas aeruginosa colonization is associated with poor outcomes in patients with bronchiectasis, including rapid decline in lung function, exacerbation frequency and hospitalization.

Methods: A cross-sectional study in Queen Mary Hospital, Hong Kong that included 350 Chinese patients with non-cystic fibrosis bronchiectasis to investigate the risk factors for Pseudomonas aeruginosa colonization and clinical implications on disease outcomes.

Discussions: Pseudomonas aeruginosa colonization was more commonly found in patients with longer duration of bronchiectasis and those on proton pump inhibitors (PPIs) with adjusted ORs of 1.066 (95% CI = 1.036-1.096, p < 0.001) and 2.815 (95% CI = 1.307-6.064, p = 0.008) respectively. Patients with Pseudomonas aeruginosa colonization have more extensive lung involvement and higher risks of exacerbation requiring hospitalization with adjusted ORs of 2.445 (95% CI = 1.283-4.657, p = 0.007) and 2.745 (95% CI = 1.012-7.449, p = 0.047) respectively. Pseudomonas aeruginosa colonization is more common among patients with longer duration of bronchiectasis and those on PPI. Pseudomonas aeruginosa colonization is associated with more extensive lung involvement and higher risks of exacerbation requiring hospitalization.

Keywords: Bronchiectasis; Bronchiectasis exacerbation; Colonization; Non-cystic fibrosis bronchiectasis; Pseudomonas aeruginosa.

MeSH terms

  • Aged
  • Aged, 80 and over
  • Bronchiectasis / diagnosis
  • Bronchiectasis / microbiology*
  • Bronchiectasis / therapy
  • Cross-Sectional Studies
  • Disease Progression
  • Female
  • Hong Kong
  • Hospitalization
  • Humans
  • Lung / microbiology*
  • Male
  • Middle Aged
  • Proton Pump Inhibitors / therapeutic use
  • Pseudomonas Infections / diagnosis
  • Pseudomonas Infections / microbiology*
  • Pseudomonas Infections / therapy
  • Pseudomonas aeruginosa / growth & development*
  • Risk Assessment
  • Risk Factors
  • Time Factors

Substances

  • Proton Pump Inhibitors